BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11921279)

  • 1. Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7.
    Langabeer SE; Gale RE; Rollinson SJ; Morgan GJ; Linch DC
    Genes Chromosomes Cancer; 2002 May; 34(1):24-32. PubMed ID: 11921279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
    Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
    Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
    Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
    Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New mechanisms of AML1 gene alteration in hematological malignancies.
    Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
    Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
    Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
    Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
    Harada H; Harada Y; Tanaka H; Kimura A; Inaba T
    Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
    Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
    Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
    Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
    Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation.
    Heller PG; Glembotsky AC; Gandhi MJ; Cummings CL; Pirola CJ; Marta RF; Kornblihtt LI; Drachman JG; Molinas FC
    Blood; 2005 Jun; 105(12):4664-70. PubMed ID: 15741216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.
    Ganly P; Walker LC; Morris CM
    Leuk Lymphoma; 2004 Jan; 45(1):1-10. PubMed ID: 15061191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    Blood; 2004 Sep; 104(5):1474-81. PubMed ID: 15142876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aml1 gene rearrangements and mutations in radiation-associated acute myeloid leukemia and myelodysplastic syndromes.
    Klymenko S; Trott K; Atkinson M; Bink K; Bebeshko V; Bazyka D; Dmytrenko I; Abramenko I; Bilous N; Misurin A; Zitzelsberger H; Rosemann M
    J Radiat Res; 2005 Jun; 46(2):249-55. PubMed ID: 15988144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.
    Song WJ; Sullivan MG; Legare RD; Hutchings S; Tan X; Kufrin D; Ratajczak J; Resende IC; Haworth C; Hock R; Loh M; Felix C; Roy DC; Busque L; Kurnit D; Willman C; Gewirtz AM; Speck NA; Bushweller JH; Li FP; Gardiner K; Poncz M; Maris JM; Gilliland DG
    Nat Genet; 1999 Oct; 23(2):166-75. PubMed ID: 10508512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C; Rowley JD; Nucifora G
    Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH).
    Roumier C; Eclache V; Imbert M; Davi F; MacIntyre E; Garand R; Talmant P; Lepelley P; Lai JL; Casasnovas O; Maynadie M; Mugneret F; Bilhou-Naberra C; Valensi F; Radford I; Mozziconacci MJ; Arnoulet C; Duchayne E; Dastugue N; Cornillet P; Daliphard S; Garnache F; Boudjerra N; Jouault H; Fenneteau O; Pedron B; Berger R; Flandrin G; Fenaux P; Preudhomme C; ;
    Blood; 2003 Feb; 101(4):1277-83. PubMed ID: 12393381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
    Osato M
    Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications.
    Asou N
    Crit Rev Oncol Hematol; 2003 Feb; 45(2):129-50. PubMed ID: 12604126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.
    Osato M; Asou N; Abdalla E; Hoshino K; Yamasaki H; Okubo T; Suzushima H; Takatsuki K; Kanno T; Shigesada K; Ito Y
    Blood; 1999 Mar; 93(6):1817-24. PubMed ID: 10068652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.